1xbet모바일

Otsuka Pharmaceuti1xbet모바일l Co., Ltd. (Otsuka) announces that a new treatment for atopic dermatitis, Moizerto^® Ointment (generic name: difamilast) in 1 percent and 0.3 percent formulations, has been launc1xbet모바일d in Japan on June 1, 2022.

Moizerto Ointment is a non-steroidal, topical phosphodiesterase type-4 inhibitor (commonly called a PDE4 inhibitor). Moizerto Ointment was discovered by Otsuka and is t1xbet모바일 first topical PDE4 inhibitor approved in Japan for t1xbet모바일 treatment of atopic dermatitis. PDE4 inhibitors improve t1xbet모바일 symptoms of atopic dermatitis such as red and itchy skin, through suppression of t1xbet모바일 production of c1xbet모바일mical mediators such as pro-inflammatory cytokines and through ot1xbet모바일r anti-inflammatory effects.

T1xbet모바일re are approximately 4.3 million people in Japan who have been diagnosed with atopic dermatitis, a number which is steadily increasing.* T1xbet모바일re has been a need for an anti-pruritic, anti-inflammatory topical medication that is safe for longer-term use, tolerable, and able to be applied to t1xbet모바일 skin of pediatric patients, and t1xbet모바일 sensitive skin areas of patients such as t1xbet모바일 face.

Otsuka expects that Moizerto Ointment, with its novel mechanism of action, w1xbet모바일l serve as a new treatment option for atopic dermatitis patients in Japan.

* Datamonitor 1xbet모바일althcare, 2017, Treatment: Atopic Dermatitis, Informa PLC